Ruinian Zheng

Ruinian Zheng


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
LZLe Zhou
Le Zhou
BHBo Han
Bo Han
YYYinjiao Yuan
Yinjiao Yuan
ZDZhuowei Dong
Zhuowei Dong
YSYijing Shi
Yijing Shi
RZRuinian Zheng
Ruinian Zheng
Background: Stomach cancer is one of the leading cancers worldwide. This article aims to analyze and assess the global burden of stomach cancer from 1990 to 2021, identify its main risk factors, and make projections for 2030 using the newly published 2021GBD database. Methods: In the Global Burden of Disease Study 2021, we analyzed the incidence, death, and DALYs related to stomach cancer. Age-standardized incidence rate (ASIR), age-standardized death rate (ASDR), and age-standardized DALYs rate were obtained and analyzed. Results: The incidence of stomach cancer increased from 980,899 in 1990 to 1,230,233 in 2021. ASIR has declined from 24.76 to 14.33 per 100,000 people. ASDR dropped from 22.01 to 11.20 per 100,000 people. The global DALYs for stomach cancer was 22,786,633, and the age-standardized DALYs rate was 262.75 per 100,000 people. Men have higher rates of ASDR, ASIR, and age-standardized DALYs compared to women. In 2021, East Asia have the highest burden of stomach cancer associated with behavioral, high-sodium diets, smoking, and dietary habits. Projections for 2030 indicate that ASIR, ASDR, and age-standardized DALYs rates will all continue to decline. Conclusion: This study found that although the ASIR and ASDR of stomach cancer have significantly declined, the absolute number of cases has continued to rise due to the continuous growth and aging of the population. In high SDI (socio-demographic index) regions, such as Western Europe and North America, the burden of stomach cancer has decreased. The high burden in low SDI regions needs to be alleviated through targeted interventions such as smoking control and improvement of dietary habits.

19 May 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YYYongkang Ye
Yongkang Ye
FYFukan Yang
Fukan Yang
ZGZhanhao Gu
Zhanhao Gu
WLWenxuan Li
Wenxuan Li
YYYinjiao Yuan
Yinjiao Yuan
ZCZhengGuo Cao
ZhengGuo Cao
Background: The initiation of fibroblast growth factor 1 (FGF1) expression coincident with the decrease of FGF2 expression is a well-documented event in prostate cancer (PCa) progression. Lactate dehydrogenase A (LDHA) and LDHB are essential metabolic products that promote tumor growth. However, the relationship between FGF1/FGF2 and LDHA/B-mediated glycolysis in PCa progression is not reported. Thus, we aimed to explore whether FGF1/2 could regulate LDHA and LDHB to promote glycolysis and explored the involved signaling pathway in PCa progression. Methods: In vitro studies used RT‒qPCR, Western blot, CCK-8 assays, and flow cytometry to analyze gene and protein expression, cell viability, apoptosis, and cell cycle in PCa cell lines. Glycolysis was assessed by measuring glucose consumption, lactate production, and extracellular acidification rate (ECAR). For in vivo studies, a xenograft mouse model of PCa was established and treated with an FGF pathway inhibitor, and tumor growth was monitored. Results: FGF1, FGF2, and LDHA were expressed at high levels in PCa cells, while LDHB expression was low. FGF1/2 positively modulated LDHA and negatively modulated LDHB in PCa cells. The depletion of FGF1, FGF2, or LDHA reduced cell proliferation, induced cell cycle arrest, and inhibited glycolysis. LDHB overexpression showed similar inhibitory effect on PCa cells. Mechanistically, we found that FGF1/2 positively regulated STAT1 and STAT1 transcriptionally activated LDHA expression while suppressed LDHB expression. Furthermore, the treatment of an FGF pathway inhibitor suppressed PCa tumor growth in mice. Conclusion: The FGF pathway facilitates glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in PCa.

18 June 2024 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
XHXiarong Hu
Xiarong Hu
QYQingyao Ye
Qingyao Ye
HLHuanQuan Lu
HuanQuan Lu
ZWZhiming Wu
Zhiming Wu
SCSiyuan Chen
Siyuan Chen
RZRuinian Zheng
Ruinian Zheng
Background: Papillary thyroid carcinoma (PTC) is a common endocrine malignancy. Studies have indicated that estrogen can regulate the expression of miRNAs in numerous malignancies. MiR-570-3p has been shown to have a regulatory function in various cancers. However, studies of the regulatory function of miR-570-3p and a direct link between estrogen (especially estradiol E2) and miR-570-3p in PTC have not been done.Methods: Expression of miR-570-3p and its downstream target DPP4 in PTC tissues and cells was predicted using bioinformatics and validated by qRT-PCR and western blot assays. We then performed a series of gain-and-loss experiments to assess the functional significance of miR-570-3p/DPP4 axis in PTC progression in vitro and in vivo. Additionally, the methylation of the miR-570-3p promoter region was examined via bioinformatics analysis and MSP. Finally, the effects of E2 on PTC progression and the correlation between DNMT1/DNMT3A and EZH2 were predicted by bioinformatic tools and proved by luciferase reporter, ChIP, and co-IP assays.Results: In PTC tumor tissues and cell lines, there was a lower expression level and a higher methylation level of miR-570-3p compared to normal tissues and cell lines. DPP4 was identified as the downstream target of miR-570-3p. Overexpression of miR-570-3p reduced the proliferative, migratory, and invasive capabilities, and promoted apoptosis, while overexpression of DPP4 reversed these effects in PTC cells. It was also discovered that DNMT1 and DNMT3A increased the CpG methylation level of the miR-570-3p promoter in an EZH2-dependent manner, which led to decreased expression of miR-570-3p. Furthermore, we observed that estrogen (E2) enhanced the methylation of miR-570-3p and suppressed its expression levels, resulting in augmented tumor growth in vivo in PTC.Conclusion: Estrogen regulates the EZH2/DNMTs/miR-570-3p/DPP4 signaling pathway to promote PTC progression.

22 December 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
LZLe Zhou
Le Zhou
ZLZhongjiang Lan
Zhongjiang Lan
BHBo Han
Bo Han
YYYinjiao Yuan
Yinjiao Yuan
ZDZhuowei Dong
Zhuowei Dong
RZRuinian Zheng
Ruinian Zheng
Background Lung adenocarcinoma (LUAD) represents a significant proportion of lung cancer cases, with immunotherapy serving as a cornerstone of treatment. Although immunotherapy has advanced significantly, the prognosis for patients in advanced stages remains suboptimal. Lactylation, a newly discovered metabolic pathway, has been recognized as a critical mechanism driving the initiation and development of many cancers, including LUAD. Using machine learning, this research aims to pinpoint lactylation-related lncRNAs (LRLs) that could serve as prognostic markers in LUAD, shedding light on tumor development and novel therapeutic avenues. Results Four LRLs (AC090115.1, AC092718.4, AC092718.6, and AL451064.1) were incorporated into a prognostic model. This model successfully categorized patients into high-risk and low-risk groups, revealing differences in prognosis. Patients in the low-risk group demonstrated a better prognosis, while the other category showed aggressive tumor characteristics and reduced responses to immunotherapy. Conclusions This study developed an association between LRLs and outcomes in lung adenocarcinoma, suggesting that they can be used as a prognostic marker and therapeutic target. The observed differences in their expression between tumor and normal tissues further underline their significance in LUAD pathogenesis. By advancing the understanding of LUAD biology, this predictive model provides a novel platform for precision medicine, paving the way for personalized therapeutic strategies and improved prognostic accuracy for LUAD patients.